Literature DB >> 18489260

Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.

Mark Frazzetto1, Cenk Suphioglu, Jiuxiang Zhu, Oleg Schmidt-Kittler, Ian G Jennings, Susan L Cranmer, Shaun P Jackson, Kenneth W Kinzler, Bert Vogelstein, Philip E Thompson.   

Abstract

The last few years have seen the identification of numerous small molecules that selectively inhibit specific class I isoforms of PI3K (phosphoinositide 3-kinase), yet little has been revealed about the molecular basis for the observed selectivities. Using site-directed mutagenesis, we have investigated one of the areas postulated as being critical to the observed selectivity. The residues Thr(886) and Lys(890) of the PI3Kgamma isoform project towards the ATP-binding pocket at the entrance to the catalytic site, but are not conserved. We have made reciprocal mutations between those residues in the beta isoform (Glu(858) and Asp(862)) and those in the alpha isoform (His(855) and Gln(859)) and evaluated the potency of a range of reported PI3K inhibitors. The results show that the potencies of beta-selective inhibitors TGX221 and TGX286 are unaffected by this change. In contrast, close analogues of these compounds, particularly the alpha-isoform-selective compound (III), are markedly influenced by the point mutations. The collected data suggests two distinct binding poses for these inhibitor classes, one of which is associated with potent PI3Kbeta activity and is not associated with the mutated residues, and a second that, in accord with earlier hypotheses, does involve this pair of non-conserved amino acids at the catalytic site entrance and contributes to the alpha-isoform-selectivity of the compounds studied.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489260      PMCID: PMC2820364          DOI: 10.1042/BJ20080512

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

Review 1.  Class I phosphoinositide 3-kinases.

Authors:  Karen E Anderson; Shaun P Jackson
Journal:  Int J Biochem Cell Biol       Date:  2003-07       Impact factor: 5.085

2.  Selective role of PI3K delta in neutrophil inflammatory responses.

Authors:  Chanchal Sadhu; Ken Dick; William T Tino; Donald E Staunton
Journal:  Biochem Biophys Res Commun       Date:  2003-09-05       Impact factor: 3.575

3.  Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.

Authors:  J Yu; Y Zhang; J McIlroy; T Rordorf-Nikolic; G A Orr; J M Backer
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

Review 4.  Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

Authors:  R Katso; K Okkenhaug; K Ahmadi; S White; J Timms; M D Waterfield
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

5.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

Review 6.  Synthesis and function of 3-phosphorylated inositol lipids.

Authors:  B Vanhaesebroeck; S J Leevers; K Ahmadi; J Timms; R Katso; P C Driscoll; R Woscholski; P J Parker; M D Waterfield
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

7.  In vitro and in vivo inhibition of rat vascular smooth muscle cell migration and proliferation by a 2-aminochromone U-86983.

Authors:  L A Erickson; P D Bonin; D G Wishka; J Morris; R J Dalga; D J Williams; G J Wilson; J L Hoover; C A Simmons; S J Humphrey
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

8.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

Authors:  Zachary A Knight; Gary G Chiang; Peter J Alaimo; Denise M Kenski; Caroline B Ho; Kristin Coan; Robert T Abraham; Kevan M Shokat
Journal:  Bioorg Med Chem       Date:  2004-09-01       Impact factor: 3.641

Review 9.  Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

Authors:  P Workman
Journal:  Biochem Soc Trans       Date:  2004-04       Impact factor: 5.407

10.  Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

Authors:  E Hirsch; V L Katanaev; C Garlanda; O Azzolino; L Pirola; L Silengo; S Sozzani; A Mantovani; F Altruda; M P Wymann
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

View more
  11 in total

Review 1.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.

Authors:  Xiaoli Bian; Wangqing Dong; Yang Zhao; Rui Sun; Wanjun Kong; Yiping Li
Journal:  J Mol Model       Date:  2014-03-16       Impact factor: 1.810

3.  Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.

Authors:  Zhaohua Zheng; Syazwani I Amran; Jiuxiang Zhu; Oleg Schmidt-Kittler; Kenneth W Kinzler; Bert Vogelstein; Peter R Shepherd; Philip E Thompson; Ian G Jennings
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

4.  L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ

Authors:  Jo-Anne Pinson; Zhaohua Zheng; Michelle S Miller; David K Chalmers; Ian G Jennings; Philip E Thompson
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

5.  Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells.

Authors:  Yunqi Zhao; Shaofeng Duan; Xing Zeng; Chunjing Liu; Neal M Davies; Benyi Li; M Laird Forrest
Journal:  Mol Pharm       Date:  2012-05-01       Impact factor: 4.939

Review 6.  Detection and manipulation of phosphoinositides.

Authors:  Olof Idevall-Hagren; Pietro De Camilli
Journal:  Biochim Biophys Acta       Date:  2014-12-13

Review 7.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

8.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

9.  Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.

Authors:  Jo-Anne Pinson; Oleg Schmidt-Kittler; Jiuxiang Zhu; Ian G Jennings; Kenneth W Kinzler; Bert Vogelstein; David K Chalmers; Philip E Thompson
Journal:  ChemMedChem       Date:  2011-01-04       Impact factor: 3.466

10.  A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Authors:  Stephen Jamieson; Jack U Flanagan; Sharada Kolekar; Christina Buchanan; Jackie D Kendall; Woo-Jeong Lee; Gordon W Rewcastle; William A Denny; Ripudaman Singh; James Dickson; Bruce C Baguley; Peter R Shepherd
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.